RxDoctor Payments Data

Ryan Marshall

Family · Chatham, NYNPI 1831398478

Payments from drug & device makers

$1,797in general payments, 2019–2025

Across 23 payments — averaging $78.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • Amgen$128
  • AstraZeneca$35
  • AbbVie$32
  • Pfizer$30
  • Actelion Pharmaceuticals US, Inc.$27
  • plus $61 from 3 others

What the payments were for

  • Consulting fees$1,38077%
  • Food & beverage$41723%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,797 in reported general payments places this provider in the 80th percentile of 8,883 family providers in New York.

See all family providers in New York

Medicare billing

Part B allowed, 2024
$57,240
Medicare patients
254
Services billed
1,276

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban65$73,687
TrulicityDulaglutide48$67,171
MounjaroTirzepatide34$51,663
OzempicSemaglutide26$44,889
JardianceEmpagliflozin30$32,727
RybelsusSemaglutide13$26,743
JanuviaSitagliptin Phosphate17$24,717
FarxigaDapagliflozin Propanediol15$20,783
Trelegy ElliptaFluticasone/Umeclidin/Vilanter31$19,389
XareltoRivaroxaban15$18,450
VraylarCariprazine Hcl11$18,142
JanumetSitagliptin Phos/Metformin Hcl12$17,429
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr13$12,229
Incruse ElliptaUmeclidinium Bromide22$8,019
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog17$6,997

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$17$118,83482 claims
PfizerEliquis$30$73,68765 claims
Novo NordiskOzempic, Rybelsus$1,484$71,63339 claims
AstraZenecaFarxiga, Symbicort$35$25,15427 claims
AbbVieVraylar, Synthroid$32$22,72866 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 8,883 family providers in New York.

Other family in Chatham

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →